Mydecine Innovations Group (OTCMKTS:MYCOF) Trading 253.7% Higher – Time to Buy?

Mydecine Innovations Group Inc. (OTCMKTS:MYCOF)’s share price rose 253.7% during trading on Monday . The stock traded as high as $0.7718 and last traded at $0.7718. Approximately 3,002 shares changed hands during mid-day trading, an increase of 1,130% from the average daily volume of 244 shares. The stock had previously closed at $0.2182.

Mydecine Innovations Group Stock Performance

The firm has a 50-day moving average of $0.14 and a 200-day moving average of $0.11.

About Mydecine Innovations Group

Mydecine Innovations Group (OTCMKTS:MYCOF) is a clinical‐stage biotechnology company dedicated to the research, development and commercialization of novel therapeutics derived from psychedelic and plant-based compounds. The company’s primary focus lies in advancing a pipeline of next‐generation product candidates targeting mental health disorders, addiction and other neurological conditions. Mydecine holds a portfolio of intellectual property that encompasses proprietary chemical entities, drug delivery systems and manufacturing processes for molecules such as 5-MeO-DMT analogs, ibogaine-derived compounds and psilocybin formulations.

Headquartered in Denver, Colorado, with additional research and manufacturing facilities in Vancouver, Canada, Mydecine operates a vertically integrated business model.